Washington, DC - The United States is gravely alarmed by continued allegations of the use of chlorine gas by the Syrian Regime to terrorize innocent civilians, this time in Idlib Province near Saraqib.

Washington, DC - Military families face all the consumer protection issues other Americans face – and then some. Frequent moves and deployments can pose additional financial challenges for servicemembers. And some of these concerns continue even after they’ve settled into civilian life. That’s why the interests of military consumers – servicemembers, veterans, and their families – are front and center at the FTC and should be an important priority for companies doing business with them.

London, England - I had a very unique opportunity this week to join a group of entrepreneurs, chefs, scientists, advocates, writers, policymakers (including the very inspiring President of Mauritius, Ameenah Gurib), and other food and agriculture experts to attend a luncheon at Clarence House in London, England, with His Royal Highness The Prince of Wales, who serves as the Patron of the Crop Trust.

San Diego, California - During an all-hands employee meeting at the San Diego Zoo Friday, philanthropist T. Denny Sanford announced that he is making a $30 million donation—the largest single gift the San Diego Zoo has ever received. This generous gift will go toward the estimated $69 million cost of constructing a brand-new, completely reimagined children’s zoo, to be named The Sanford Children’s Zoo.

Holtville, California - Holtville Athletic Club Annual Rib Cook-Off Extravaganza

  • Samaha Park - Holtville, California  92250
  • Saturday, January 27, 2018 - 10:00am PST – Till all the ribs are gone approximately 2:00pm
  • Teams: (By Invitation)
  • Admission: Free

Washington, DC - The U.S. Food and Drug Administration Friday expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a “BRCA” gene mutation. Patients are selected for treatment with Lynparza based on an FDA-approved genetic test, called the BRACAnalysis CDx.